MPM Capital
MPM Capital (MPM BioImpact) is a Boston-based biotech investment firm founded in 1996 that builds and funds private and public therapeutic companies across oncology, immunology, neuroscience, and genetic medicine, generating returns through portfolio exits and fund management fees.
- Company typePrivate
- Founded1996
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What MPM Capital does
MPM Capital, operating under the brand MPM BioImpact LLC, is a Boston-headquartered biotechnology investment firm founded in 1996 that invests across private and public companies throughout the drug development lifecycle. The firm combines capital deployment with hands-on company creation, building businesses from scientific breakthroughs (for example, Orna Therapeutics from MIT circular RNA research and Aktis Oncology from an in-house radiopharmaceutical concept) and supporting them through clinical and regulatory milestones toward exits.
The investment portfolio spans oncology, immunology, neuroscience, and genetic medicine, with notable positions including argenx (developer of the first approved FcRn blocker VYVGART), Orna Therapeutics (circular RNA medicines acquired by Eli Lilly for approximately $2.4 billion), Aktis Oncology (alpha radiopharmaceuticals, IPO'd in 2025), Reunion Neuroscience (psychedelic-inspired 5-HT2AR agonist RE104, FDA Breakthrough Therapy Designation 2026), and Firefly Bio (degrader-antibody conjugates, acquired by Johnson & Johnson). The firm cites 30+ years of biotech investing experience, 60 FDA-approved drugs associated with portfolio companies, and 120+ M&A and IPO events as core track-record metrics.
MPM BioImpact generates revenue through management fees on investment funds and carried interest from portfolio exits rather than product sales. The firm is privately held with 11-50 employees and operates with no disclosed AI/ML or software-product capabilities, distributing capital and strategic support rather than products or services to end customers.
MPM Capital firmographics
Firmographics- Name
- MPM Capital
- Legal name
- MPM BioImpact LLC
- Website
- https://mpmcapital.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MPM Capital (MPM BioImpact) is a Boston-based biotech investment firm founded in 1996 that builds and funds private and public therapeutic companies across oncology, immunology, neuroscience, and genetic medicine, generating returns through portfolio exits and fund management fees.
- Ownership category
- akta.pro rank
MPM Capital industry classification
Industry- Product category
- Venture Capital / Life Sciences Investing
- NAICS
- Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)
Keywords
Where MPM Capital is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MPM Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Marketing channels3 records
MPM Capital product offering
Product offeringCore offering
MPM Capital (also operating as MPM BioImpact) is a biotechnology investment firm that manages venture capital and private equity funds providing capital and strategic support to private and public biotech companies across all stages of drug development—from discovery through regulatory approval and commercialization. The firm focuses on oncology, immunology, neurology, and genetic medicine, and is known for both funding and actively building companies around transformative therapeutic platforms.
Product overview
MPM BioImpact is a biotech investment and venture capital firm that builds and funds companies across the drug development process. Rather than offering a unified software platform or product suite, the firm operates investment funds that provide capital and strategic support to portfolio companies developing therapeutics. The portfolio includes Orna Therapeutics (circular RNA medicines), Aktis Oncology (alpha radiopharmaceuticals), Reunion Neuroscience (psychedelic-inspired mental health treatments), argenx (FcRn blocker VYVGART), and numerous other biotech companies across oncology, immunology, neurology, and genetic medicine.
Differentiator
Problem solved
Functional benefit
Products and services
- MPM BioImpact Investment Funds
Quantifiable outcome
- 60 FDA-approved drugs
- +2 more outcomes
Companies that use MPM Capital
Customer profileSegments1 record
Ideal customer profiles1 record
MPM Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
MPM Capital partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Vertex PharmaceuticalscoreOrna Therapeutics, a portfolio company founded and built by MPM BioImpact, established a strategic collaboration with Vertex Pharmaceuticals to develop next generation approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT). This collaboration leverages Orna's circular RNA technology platform combined with Vertex's expertise in genetic diseases.
Scale indicators3 records
Recent moves7 records
Expansion highlights4 records
MPM Capital competitors and assessment
Company assessmentDirect peers
- Atlas Venture: Boston-based early-stage biotech venture firm that builds and funds therapeutic companies from inception — directly comparable to MPM's company-creation model in life sciences.
- Flagship Pioneering: Cambridge-based biotech innovation engine that originates and grows breakthrough therapeutic platforms — comparable to MPM in modality-driven company creation.
- Third Rock Ventures: Boston-based biotech VC focused on building and launching therapeutic companies — closely aligned with MPM's entrepreneur-led, company-creation approach.
- ARCH Venture Partners: Long-tenured biotech-focused VC investing across private and public companies across drug development — comparable mandate and stage breadth to MPM.
- OrbiMed Advisors: Healthcare-dedicated investment firm covering therapeutics, devices, and diagnostics across stages — directly comparable to MPM's healthcare-only focus.
- Baker Bros. Advisors: Biotech-focused investment adviser investing across public and private therapeutics — directly comparable to MPM as a long-duration biotech specialist.
- 5AM Ventures: Early-stage life-sciences VC building companies around breakthrough science — comparable company-creation orientation and stage profile to MPM.
- Versant Ventures: Healthcare-focused VC with dedicated biotech and medtech franchises — comparable stage breadth and therapeutic focus to MPM.
- RA Capital Management: Healthcare-focused crossover and public-private investor — comparable mandate of investing across private and public biotech companies.
Broad incumbents
- Andreessen Horowitz (a16z Bio): Large generalist VC with a dedicated Bio/Health fund targeting therapeutics platforms — overlapping with MPM's biotech investment activity but operating at much greater scale and across broader sectors.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MPM Capital social profiles
Digital presenceMPM Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
MPM Capital leadership team
Management profileNumber of profiles
Profiles9 records
MPM Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MPM Capital M&A and investment
M&A and investmentM&A2 records
Investments303 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MPM Capital
What does MPM Capital do?
MPM Capital (also operating as MPM BioImpact) is a biotechnology investment firm that manages venture capital and private equity funds providing capital and strategic support to private and public biotech companies across all stages of drug development—from discovery through regulatory approval and commercialization. The firm focuses on oncology, immunology, neurology, and genetic medicine, and is known for both funding and actively building companies around transformative therapeutic platforms.
When was MPM Capital founded?
MPM Capital was founded in 1996. It employs 11 to 50 people.
Where is MPM Capital based?
MPM Capital is headquartered in Boston, United States, in the North America region.
Who are MPM Capital's main competitors?
Direct peers on record are Atlas Venture, Flagship Pioneering, Third Rock Ventures, ARCH Venture Partners, OrbiMed Advisors, Baker Bros. Advisors, 5AM Ventures, Versant Ventures and RA Capital Management. Andreessen Horowitz (a16z Bio) is listed as a broad incumbent.
Does MPM Capital have an API?
No public API is recorded for MPM Capital.
What industry is MPM Capital in?
MPM Capital's product category is Venture Capital / Life Sciences Investing. Its primary akta.pro industry code is FSANAHAN, Corporate Strategic Real Assets & Infrastructure Venture Investing. Its NAICS code is 523940 and its SIC code is 6282.